{"id":"amlodipine-perindopril","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Peripheral edema"},{"rate":"5-8","effect":"Headache"},{"rate":"3-7","effect":"Dizziness"},{"rate":"2-5","effect":"Cough"},{"rate":"2-4","effect":"Fatigue"},{"rate":"2-3","effect":"Flushing"}]},"_chembl":null,"_dailymed":{"setId":"eaa2bbbc-5fcc-4f15-a51c-c4e1bf320c90","title":"PRESTALIA (PERINDOPRIL ARGININE AND AMLODIPINE BESYLATE) TABLET [ADHERA THERAPEUTICS, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amlodipine is a dihydropyridine calcium channel blocker that prevents calcium influx into vascular smooth muscle cells, causing vasodilation. Perindopril is an ACE inhibitor that blocks the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. The combination provides complementary antihypertensive effects through different mechanisms.","oneSentence":"Amlodipine relaxes blood vessels by blocking calcium channels, while perindopril lowers blood pressure by inhibiting angiotensin-converting enzyme (ACE), together reducing hypertension.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:29:47.656Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Hypertension in patients with coronary artery disease"}]},"trialDetails":[{"nctId":"NCT04040634","phase":"NA","title":"Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hospital Israelita Albert Einstein","startDate":"2019-08-08","conditions":"Diabetes Mellitus, High Blood Pressure, Cardiovascular Diseases","enrollment":9476},{"nctId":"NCT05780710","phase":"NA","title":"OBPM_Meds2023: Multicentric Prospective Clinical Study to Evaluate the Aktiia Optical Blood Pressure Monitoring (OBPM) Device Compared to Standard Home Blood Pressure Monitoring (HBPM) in Hypertensive Patients When Blood Pressure Lowering Medications Intake","status":"RECRUITING","sponsor":"Aktiia SA","startDate":"2023-06-29","conditions":"Hypertension","enrollment":35},{"nctId":"NCT07262710","phase":"","title":"Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","startDate":"2025-12-01","conditions":"Post-stroke Pneumonia","enrollment":13656},{"nctId":"NCT07259733","phase":"NA","title":"Rapid Management of Resistant Hypertension in the Public Health System (Fast Control)","status":"RECRUITING","sponsor":"Instituto Dante Pazzanese de Cardiologia","startDate":"2023-07-15","conditions":"Apparent Resistant Hypertension, Hypertension, High Blood Pressure","enrollment":142},{"nctId":"NCT06259175","phase":"","title":"Evaluation of the Antihypertensive effectIveness, Tolerability, and Adherence With Amlodipine/ Indapamide/ Perindopril Triple Single-pill Combination in Hypertensive Patients Without Concomitant Antihypertensive Therapy (TRIPTYCH)","status":"COMPLETED","sponsor":"Servier Russia","startDate":"2024-05-01","conditions":"Arterial Hypertension, HTN","enrollment":396},{"nctId":"NCT05288400","phase":"PHASE3","title":"Evaluation of the Clinical Efficacy and Safety of Amlodipine 5mg/ Bisoprolol Fumarate 5mg /Perindopril Arginine 5mg Fixed-dose Combination in Capsule and Free Monotherapy at the Same Dose in Patients With Uncontrolled Essential Hypertension.","status":"COMPLETED","sponsor":"Servier","startDate":"2018-05-14","conditions":"Essential Hypertension","enrollment":150},{"nctId":"NCT06704815","phase":"","title":"Observational Cohort Study Evaluating the Effectiveness of an Educational Program (NGAYDAUTIEN) in Combination With Perindopril and Amlodipine Single-Pill Combination in Hypertensive Patients naïve of Antihypertensive Treatments.","status":"COMPLETED","sponsor":"Servier Affaires Médicales","startDate":"2023-01-31","conditions":"Hypertension","enrollment":400},{"nctId":"NCT05683301","phase":"PHASE4","title":"Treatment Optimisation for Blood Pressure With Single-Pill Combinations in India","status":"COMPLETED","sponsor":"Centre for Chronic Disease Control, India","startDate":"2022-08-30","conditions":"Primary Hypertension","enrollment":1981},{"nctId":"NCT06515678","phase":"","title":"Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Hospitalier Pitie-Salpetriere","startDate":"2024-05-20","conditions":"Ovarian Cancer, Antiangiogenic-Associated Hypertension, Adjuvant Bevacizumab","enrollment":9464},{"nctId":"NCT05820880","phase":"PHASE3","title":"Efficacy and Safety of Perindopril 5 mg / Indapamide 1.25 mg / Amlodipine 5 mg Fixed Combination in Hypertension","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2019-05-06","conditions":"Hypertension","enrollment":532},{"nctId":"NCT05764317","phase":"","title":"Description of the Effectiveness, Safety, Tolerability and Adherence to Amlodipine/Atorvastatin/Perindopril Single Pill Combination Treatment in Patients With Arterial Hypertension and Dyslipidemia (TARGET)","status":"COMPLETED","sponsor":"Servier Russia","startDate":"2023-04-30","conditions":"Arterial Hypertension, HTN","enrollment":409},{"nctId":"NCT06275763","phase":"PHASE4","title":"Optimal Medical Treatment of Difficult-to-treat Hypertension","status":"UNKNOWN","sponsor":"National Institute of Cardiology, Warsaw, Poland","startDate":"2023-10-20","conditions":"Hypertension","enrollment":2500},{"nctId":"NCT04036409","phase":"NA","title":"Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Stroke Patients","status":"UNKNOWN","sponsor":"Hospital Israelita Albert Einstein","startDate":"2019-08-05","conditions":"Ischemic Stroke, Blood Pressure, Cognitive Impairment","enrollment":4369},{"nctId":"NCT05940909","phase":"PHASE1","title":"Bioequivalence Study of Perindopril /Amlodipine/Indapamide 8 mg (10 mg)/2.5 mg/10 mg Tablets in Healthy Volunteers Under Fasting Conditions","status":"UNKNOWN","sponsor":"Pharmtechnology LLC","startDate":"2023-06-24","conditions":"Bioequivalence","enrollment":50},{"nctId":"NCT05470764","phase":"PHASE1","title":"Bioequivalence Study of 8 mg Perindopril Tert-Butylamine / 2.5 mg Indapamide / 10 mg Amlodipine Tablets Versus 10 mg Perindopril Arginine / 2.5 mg Indapamide / 10 mg Amlodipine Film-Coated Tablets in Healthy Volunteers","status":"COMPLETED","sponsor":"Darnitsa Pharmaceutical Company","startDate":"2021-05-30","conditions":"Bioequivalence, Healthy Subjects","enrollment":52},{"nctId":"NCT00231803","phase":"NA","title":"The Canadian Prevention of Renal and Cardiovascular Endpoints Trial","status":"COMPLETED","sponsor":"Brendan Barrett","startDate":"2005-04","conditions":"Chronic Kidney Disease","enrollment":474},{"nctId":"NCT02742467","phase":"PHASE4","title":"Comparison of Three Combination Therapies in Lowering Blood Pressure in Black Africans","status":"COMPLETED","sponsor":"University of Abuja","startDate":"2017-06-07","conditions":"Hypertension","enrollment":702},{"nctId":"NCT03722524","phase":"","title":"The Use of TrIple Fixed-dose Combination in the Treatment of Arterial Hypertension","status":"COMPLETED","sponsor":"Servier Russia","startDate":"2018-10-01","conditions":"Arterial Hypertension","enrollment":1247},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT01118520","phase":"PHASE2","title":"AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition on RisK)","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2011-09","conditions":"Abdominal Aortic Aneurysm","enrollment":224},{"nctId":"NCT03738761","phase":"PHASE4","title":"Management of Newly Diagnosed and Uncontrolled Hypertension With Fixed-Dose Combination of Perindopril/Amlodipine and Perindopril/Indapamide/Amlodipine","status":"COMPLETED","sponsor":"KRKA","startDate":"2018-02-13","conditions":"Hypertension","enrollment":471},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":"Hypertension, COVID-19","enrollment":2414},{"nctId":"NCT04306627","phase":"PHASE4","title":"Effect of Atorvastatin on Carotid Intima Media Thickness","status":"UNKNOWN","sponsor":"Yerevan State Medical University","startDate":"2020-04-15","conditions":"Essential Hypertension, Hypercholesterolemia","enrollment":200},{"nctId":"NCT03047538","phase":"PHASE4","title":"Fixed Combination for Lipid and Blood Pressure Control","status":"WITHDRAWN","sponsor":"Charles University, Czech Republic","startDate":"2017-09-01","conditions":"Arterial Hypertension, Dyslipidemias, Blood Pressure","enrollment":""},{"nctId":"NCT02449811","phase":"","title":"RAS Peptide Profiles in Patients With Arterial Hypertension","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2015-04","conditions":"Essential Hypertension","enrollment":107},{"nctId":"NCT01101009","phase":"PHASE4","title":"Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood Pressure","status":"COMPLETED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2010-04","conditions":"Hypertension","enrollment":486},{"nctId":"NCT03747978","phase":"PHASE4","title":"Short-term Effects of Perindopril-amlodipine Versus Perindopril-indapamide in Type 2 Diabetes","status":"COMPLETED","sponsor":"Yaounde Central Hospital","startDate":"2016-10-01","conditions":"Diabetes Mellitus, Type 2, Hypertension","enrollment":30},{"nctId":"NCT02655029","phase":"","title":"Study for the Recording of Adherence to Treatment With Perindopril/Indapamide/Amlodipine Fixed Dose Combination","status":"COMPLETED","sponsor":"Servier Hellas Pharmaceuticals Ltd.","startDate":"2015-11-25","conditions":"Adherence to Medication Regime, Hypertensive Disease","enrollment":2285},{"nctId":"NCT02995954","phase":"PHASE4","title":"Fixed vs Free Dose of ACEi/CCB Combination Therapy","status":"COMPLETED","sponsor":"Guido Iaccarino","startDate":"2014-01","conditions":"Hypertension","enrollment":100},{"nctId":"NCT02710552","phase":"PHASE4","title":"Low-dose Combination of Three Antihypertensive Drugs","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2016-04","conditions":"Arterial Hypertension","enrollment":100},{"nctId":"NCT02710539","phase":"PHASE4","title":"Once-daily Fixed Combination of Three Antihypertensive Drugs","status":"UNKNOWN","sponsor":"University of Roma La Sapienza","startDate":"2016-04","conditions":"Arterial Hypertension","enrollment":100},{"nctId":"NCT01556997","phase":"PHASE3","title":"Perindopril Amlodipine for the Treatment of Hypertension","status":"COMPLETED","sponsor":"Symplmed Pharmaceuticals LLC","startDate":"2012-02","conditions":"Essential Hypertension","enrollment":837},{"nctId":"NCT01089452","phase":"PHASE4","title":"Angiotensin Receptor Blocker Combined With Calcium Antagonist Evaluation of Safety and Lowering of Systolic Blood Pressure Study","status":"WITHDRAWN","sponsor":"Monash University","startDate":"","conditions":"Hypertension","enrollment":""},{"nctId":"NCT02213224","phase":"PHASE4","title":"Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2014-08","conditions":"Nonalcoholic Fatty Liver Disease (NAFLD)","enrollment":180},{"nctId":"NCT00684489","phase":"NA","title":"Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2003-09","conditions":"Hypertension","enrollment":52}],"_emaApprovals":[],"_faersSignals":[{"count":40,"reaction":"DRUG INTERACTION"},{"count":23,"reaction":"HYPOTENSION"},{"count":20,"reaction":"TOXICITY TO VARIOUS AGENTS"},{"count":19,"reaction":"COUGH"},{"count":18,"reaction":"OEDEMA PERIPHERAL"},{"count":18,"reaction":"OFF LABEL USE"},{"count":17,"reaction":"NAUSEA"},{"count":16,"reaction":"CARDIAC FAILURE"},{"count":16,"reaction":"DYSPNOEA"},{"count":16,"reaction":"LACTIC ACIDOSIS"}],"_approvalHistory":[],"publicationCount":45,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Amlodipine + Perindopril","genericName":"Amlodipine + Perindopril","companyName":"Centre for Chronic Disease Control, India","companyId":"centre-for-chronic-disease-control-india","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Amlodipine relaxes blood vessels by blocking calcium channels, while perindopril lowers blood pressure by inhibiting angiotensin-converting enzyme (ACE), together reducing hypertension. Used for Hypertension, Hypertension in patients with coronary artery disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}